Last reviewed · How we verify
L19TNF and CCNU
At a glance
| Generic name | L19TNF and CCNU |
|---|---|
| Sponsor | Philogen S.p.A. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma (PHASE2)
- A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence (PHASE2)
- Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression (PHASE1)
- A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L19TNF and CCNU CI brief — competitive landscape report
- L19TNF and CCNU updates RSS · CI watch RSS
- Philogen S.p.A. portfolio CI